HC Wainwright Issues Optimistic Forecast for ACRS Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Aclaris Therapeutics in a report released on Wednesday, October 28th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.61) per share for the year, up from their prior forecast of ($0.62). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.55) EPS.

ACRS has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Canaccord Genuity Group started coverage on shares of Aclaris Therapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $10.00 price objective on the stock. Wedbush lowered their target price on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Wednesday. Craig Hallum set a $9.00 target price on shares of Aclaris Therapeutics in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Three investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Aclaris Therapeutics has a consensus rating of “Buy” and a consensus price target of $11.00.

Aclaris Therapeutics Stock Up 0.8%

NASDAQ:ACRS opened at $3.99 on Friday. Aclaris Therapeutics has a fifty-two week low of $2.10 and a fifty-two week high of $6.60. The stock has a market cap of $557.90 million, a PE ratio of -6.88 and a beta of 0.87. The firm’s fifty day simple moving average is $4.93 and its 200-day simple moving average is $4.51.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $1.63 million during the quarter, compared to the consensus estimate of $1.38 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Aclaris Therapeutics during the 2nd quarter worth about $53,096,000. Rock Springs Capital Management LP lifted its holdings in Aclaris Therapeutics by 0.4% in the 1st quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company’s stock valued at $16,772,000 after purchasing an additional 18,909 shares in the last quarter. Braidwell LP lifted its holdings in Aclaris Therapeutics by 26.1% in the 2nd quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock valued at $11,333,000 after purchasing an additional 443,232 shares in the last quarter. Palo Alto Investors LP acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth about $8,535,045. Finally, Kalehua Capital Management LLC acquired a new stake in shares of Aclaris Therapeutics during the 1st quarter worth about $6,871,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.